US633410A
(en)
|
1898-09-22 |
1899-09-19 |
George A Ames |
Ice-cutter.
|
US2429008A
(en)
|
1945-12-01 |
1947-10-14 |
Diamond Chain & Mfg Company |
Sprocket or gear
|
US3720760A
(en)
|
1968-09-06 |
1973-03-13 |
Pharmacia Ab |
Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples
|
US3896111A
(en)
|
1973-02-20 |
1975-07-22 |
Research Corp |
Ansa macrolides
|
US4151042A
(en)
|
1977-03-31 |
1979-04-24 |
Takeda Chemical Industries, Ltd. |
Method for producing maytansinol and its derivatives
|
US4137230A
(en)
|
1977-11-14 |
1979-01-30 |
Takeda Chemical Industries, Ltd. |
Method for the production of maytansinoids
|
US4307016A
(en)
|
1978-03-24 |
1981-12-22 |
Takeda Chemical Industries, Ltd. |
Demethyl maytansinoids
|
US4265814A
(en)
|
1978-03-24 |
1981-05-05 |
Takeda Chemical Industries |
Matansinol 3-n-hexadecanoate
|
JPS5562090A
(en)
|
1978-10-27 |
1980-05-10 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
JPS55164687A
(en)
|
1979-06-11 |
1980-12-22 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
JPS5566585A
(en)
|
1978-11-14 |
1980-05-20 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
US4256746A
(en)
|
1978-11-14 |
1981-03-17 |
Takeda Chemical Industries |
Dechloromaytansinoids, their pharmaceutical compositions and method of use
|
JPS55102583A
(en)
|
1979-01-31 |
1980-08-05 |
Takeda Chem Ind Ltd |
20-acyloxy-20-demethylmaytansinoid compound
|
JPS55162791A
(en)
|
1979-06-05 |
1980-12-18 |
Takeda Chem Ind Ltd |
Antibiotic c-15003pnd and its preparation
|
JPS55164685A
(en)
|
1979-06-08 |
1980-12-22 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
JPS55164686A
(en)
|
1979-06-11 |
1980-12-22 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
US4309428A
(en)
|
1979-07-30 |
1982-01-05 |
Takeda Chemical Industries, Ltd. |
Maytansinoids
|
JPS5645483A
(en)
|
1979-09-19 |
1981-04-25 |
Takeda Chem Ind Ltd |
C-15003phm and its preparation
|
EP0028683A1
(en)
|
1979-09-21 |
1981-05-20 |
Takeda Chemical Industries, Ltd. |
Antibiotic C-15003 PHO and production thereof
|
JPS5645485A
(en)
|
1979-09-21 |
1981-04-25 |
Takeda Chem Ind Ltd |
Production of c-15003pnd
|
US4458066A
(en)
|
1980-02-29 |
1984-07-03 |
University Patents, Inc. |
Process for preparing polynucleotides
|
WO1982001188A1
(en)
|
1980-10-08 |
1982-04-15 |
Takeda Chemical Industries Ltd |
4,5-deoxymaytansinoide compounds and process for preparing same
|
US4450254A
(en)
|
1980-11-03 |
1984-05-22 |
Standard Oil Company |
Impact improvement of high nitrile resins
|
US4313946A
(en)
|
1981-01-27 |
1982-02-02 |
The United States Of America As Represented By The Secretary Of Agriculture |
Chemotherapeutically active maytansinoids from Trewia nudiflora
|
US4315929A
(en)
|
1981-01-27 |
1982-02-16 |
The United States Of America As Represented By The Secretary Of Agriculture |
Method of controlling the European corn borer with trewiasine
|
JPS57192389A
(en)
|
1981-05-20 |
1982-11-26 |
Takeda Chem Ind Ltd |
Novel maytansinoid
|
DE3378250D1
(en)
|
1982-04-22 |
1988-11-24 |
Ici Plc |
Continuous release formulations
|
US4522811A
(en)
|
1982-07-08 |
1985-06-11 |
Syntex (U.S.A.) Inc. |
Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
|
US5128326A
(en)
|
1984-12-06 |
1992-07-07 |
Biomatrix, Inc. |
Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
|
US5374548A
(en)
|
1986-05-02 |
1994-12-20 |
Genentech, Inc. |
Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
|
MX9203291A
(es)
|
1985-06-26 |
1992-08-01 |
Liposome Co Inc |
Metodo para acoplamiento de liposomas.
|
WO1988007089A1
(en)
|
1987-03-18 |
1988-09-22 |
Medical Research Council |
Altered antibodies
|
US4880078A
(en)
|
1987-06-29 |
1989-11-14 |
Honda Giken Kogyo Kabushiki Kaisha |
Exhaust muffler
|
US5677425A
(en)
|
1987-09-04 |
1997-10-14 |
Celltech Therapeutics Limited |
Recombinant antibody
|
US5108921A
(en)
|
1989-04-03 |
1992-04-28 |
Purdue Research Foundation |
Method for enhanced transmembrane transport of exogenous molecules
|
AU6430190A
(en)
|
1989-10-10 |
1991-05-16 |
Pitman-Moore, Inc. |
Sustained release composition for macromolecular proteins
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
WO1991006287A1
(en)
|
1989-11-06 |
1991-05-16 |
Enzytech, Inc. |
Protein microspheres and methods of using them
|
ES2181673T3
(es)
|
1991-05-01 |
2003-03-01 |
Jackson H M Found Military Med |
Procedimiento de tratamiento de las enfermedades respiratorias infecciosas.
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
US5912015A
(en)
|
1992-03-12 |
1999-06-15 |
Alkermes Controlled Therapeutics, Inc. |
Modulated release from biocompatible polymers
|
CA2076465C
(en)
|
1992-03-25 |
2002-11-26 |
Ravi V. J. Chari |
Cell binding agent conjugates of analogues and derivatives of cc-1065
|
WO1993022332A2
(en)
|
1992-04-24 |
1993-11-11 |
Board Of Regents, The University Of Texas System |
Recombinant production of immunoglobulin-like domains in prokaryotic cells
|
US5934272A
(en)
|
1993-01-29 |
1999-08-10 |
Aradigm Corporation |
Device and method of creating aerosolized mist of respiratory drug
|
EP0714409A1
(en)
|
1993-06-16 |
1996-06-05 |
Celltech Therapeutics Limited |
Antibodies
|
US5605793A
(en)
|
1994-02-17 |
1997-02-25 |
Affymax Technologies N.V. |
Methods for in vitro recombination
|
US5837458A
(en)
|
1994-02-17 |
1998-11-17 |
Maxygen, Inc. |
Methods and compositions for cellular and metabolic engineering
|
US5834252A
(en)
|
1995-04-18 |
1998-11-10 |
Glaxo Group Limited |
End-complementary polymerase reaction
|
US6132764A
(en)
|
1994-08-05 |
2000-10-17 |
Targesome, Inc. |
Targeted polymerized liposome diagnostic and treatment agents
|
ATE252894T1
(de)
|
1995-01-05 |
2003-11-15 |
Univ Michigan |
Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung
|
US5641870A
(en)
|
1995-04-20 |
1997-06-24 |
Genentech, Inc. |
Low pH hydrophobic interaction chromatography for antibody purification
|
US6019968A
(en)
|
1995-04-14 |
2000-02-01 |
Inhale Therapeutic Systems, Inc. |
Dispersible antibody compositions and methods for their preparation and use
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
CA2230494A1
(en)
|
1995-08-31 |
1997-03-06 |
Alkermes Controlled Therapeutics Inc. |
Composition for sustained release of an agent
|
JP2000506165A
(ja)
|
1996-03-04 |
2000-05-23 |
ザ ペン ステイト リサーチ ファウンデーション |
細胞インターナリゼーションを増強するための物質および方法
|
US5874064A
(en)
|
1996-05-24 |
1999-02-23 |
Massachusetts Institute Of Technology |
Aerodynamically light particles for pulmonary drug delivery
|
US5985309A
(en)
|
1996-05-24 |
1999-11-16 |
Massachusetts Institute Of Technology |
Preparation of particles for inhalation
|
US5855913A
(en)
|
1997-01-16 |
1999-01-05 |
Massachusetts Instite Of Technology |
Particles incorporating surfactants for pulmonary drug delivery
|
US6056973A
(en)
|
1996-10-11 |
2000-05-02 |
Sequus Pharmaceuticals, Inc. |
Therapeutic liposome composition and method of preparation
|
PT954282E
(pt)
|
1997-01-16 |
2005-06-30 |
Massachusetts Inst Technology |
Preparacao de particulas para inalacao
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
EP1724282B1
(en)
|
1997-05-21 |
2013-05-15 |
Merck Patent GmbH |
Method for the production of non-immunogenic proteins
|
EP0985039B1
(en)
|
1997-06-12 |
2008-02-20 |
Novartis International Pharmaceutical Ltd. |
Artificial antibody polypeptides
|
US5989463A
(en)
|
1997-09-24 |
1999-11-23 |
Alkermes Controlled Therapeutics, Inc. |
Methods for fabricating polymer-based controlled release devices
|
SE512663C2
(sv)
|
1997-10-23 |
2000-04-17 |
Biogram Ab |
Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
ES2198922T3
(es)
|
1998-06-24 |
2004-02-01 |
Advanced Inhalation Research, Inc. |
Particulas porosas grandes emitadas por un inhalador.
|
ATE349438T1
(de)
|
1999-11-24 |
2007-01-15 |
Immunogen Inc |
Cytotoxische wirkstoffe enthaltend taxane und deren therapeutische anwendung
|
WO2001049698A1
(en)
|
1999-12-29 |
2001-07-12 |
Immunogen, Inc. |
Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
|
US6411163B1
(en)
|
2000-08-14 |
2002-06-25 |
Intersil Americas Inc. |
Transconductance amplifier circuit
|
US6441163B1
(en)
|
2001-05-31 |
2002-08-27 |
Immunogen, Inc. |
Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
|
TWI275390B
(en)
|
2002-04-30 |
2007-03-11 |
Wyeth Corp |
Process for the preparation of 7-substituted-3- quinolinecarbonitriles
|
GB0215823D0
(en)
|
2002-07-09 |
2002-08-14 |
Astrazeneca Ab |
Quinazoline derivatives
|
ES2318167T3
(es)
|
2002-07-15 |
2009-05-01 |
The Trustees Of Princeton University |
Compuestos de union a iap.
|
CN101899114A
(zh)
|
2002-12-23 |
2010-12-01 |
惠氏公司 |
抗pd-1抗体及其用途
|
US8088387B2
(en)
|
2003-10-10 |
2012-01-03 |
Immunogen Inc. |
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
|
US7399865B2
(en)
|
2003-09-15 |
2008-07-15 |
Wyeth |
Protein tyrosine kinase enzyme inhibitors
|
JP2007523061A
(ja)
|
2004-01-16 |
2007-08-16 |
ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン |
Smacペプチドミメティクスおよびその使用法
|
JP2007522116A
(ja)
|
2004-01-16 |
2007-08-09 |
ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン |
コンホメーションが制約されたSmac模倣物およびその使用
|
EP1740173A4
(en)
|
2004-03-23 |
2009-05-27 |
Genentech Inc |
AZABICYCLOOCTAN IAP INHIBITORS
|
JP4691549B2
(ja)
|
2004-04-07 |
2011-06-01 |
ノバルティス アーゲー |
Iapの阻害剤
|
KR100984459B1
(ko)
|
2004-07-02 |
2010-09-29 |
제넨테크, 인크. |
Iap의 억제제
|
WO2006010118A2
(en)
|
2004-07-09 |
2006-01-26 |
The Regents Of The University Of Michigan |
Conformationally constrained smac mimetics and the uses thereof
|
WO2006017295A2
(en)
|
2004-07-12 |
2006-02-16 |
Idun Pharmaceuticals, Inc. |
Tetrapeptide analogs
|
CA2574040C
(en)
|
2004-07-15 |
2014-05-06 |
Tetralogic Pharmaceuticals Corporation |
Iap binding compounds
|
ATE477254T1
(de)
|
2004-12-20 |
2010-08-15 |
Genentech Inc |
Pyrrolidine als inhibitoren von iap
|
AU2006213662B2
(en)
|
2005-02-11 |
2010-08-05 |
Immunogen, Inc. |
Process for preparing stable drug conjugates
|
US20110166319A1
(en)
|
2005-02-11 |
2011-07-07 |
Immunogen, Inc. |
Process for preparing purified drug conjugates
|
CA2970873C
(en)
|
2005-05-09 |
2022-05-17 |
E. R. Squibb & Sons, L.L.C. |
Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
CN104356236B
(zh)
|
2005-07-01 |
2020-07-03 |
E.R.施贵宝&圣斯有限责任公司 |
抗程序性死亡配体1(pd-l1)的人单克隆抗体
|
WO2007003216A1
(en)
*
|
2005-07-06 |
2007-01-11 |
Universidad Autónoma de Madrid |
Anti-ccr7 receptor antibodies for the treatment of cancer
|
ES2533992T3
(es)
|
2005-08-24 |
2015-04-16 |
Immunogen, Inc. |
Procedimiento para preparar conjugados de anticuerpo maitansinoide
|
JP2009506790A
(ja)
|
2005-09-07 |
2009-02-19 |
メディミューン,エルエルシー |
毒素とコンジュゲートしたeph受容体抗体
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
MX2009011783A
(es)
|
2007-04-30 |
2009-12-04 |
Genentech Inc |
Inhibidores de iap.
|
EP3222634A1
(en)
|
2007-06-18 |
2017-09-27 |
Merck Sharp & Dohme B.V. |
Antibodies to human programmed death receptor pd-1
|
PE20140100A1
(es)
|
2007-09-12 |
2014-02-12 |
Genentech Inc |
Combinaciones de compuestos inhibidores de fosfoinositida 3-quinasa y agentes quimioterapeuticos
|
US8354528B2
(en)
|
2007-10-25 |
2013-01-15 |
Genentech, Inc. |
Process for making thienopyrimidine compounds
|
US8747847B2
(en)
|
2008-02-11 |
2014-06-10 |
Curetech Ltd. |
Monoclonal antibodies for tumor treatment
|
EP2262837A4
(en)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
PD-1 BINDING PROTEINS
|
KR20230003298A
(ko)
|
2008-04-30 |
2023-01-05 |
이뮤노젠 아이엔씨 |
가교제 및 그 용도
|
US8168784B2
(en)
|
2008-06-20 |
2012-05-01 |
Abbott Laboratories |
Processes to make apoptosis promoters
|
WO2010027423A2
(en)
|
2008-08-25 |
2010-03-11 |
Amplimmune, Inc. |
Compositions of pd-1 antagonists and methods of use
|
KR20110074850A
(ko)
|
2008-08-25 |
2011-07-04 |
앰플리뮨, 인크. |
Pd-1 길항제 및 그의 사용 방법
|
PE20120341A1
(es)
|
2008-12-09 |
2012-04-24 |
Genentech Inc |
Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t
|
WO2010089411A2
(en)
|
2009-02-09 |
2010-08-12 |
Universite De La Mediterranee |
Pd-1 antibodies and pd-l1 antibodies and uses thereof
|
KR102444399B1
(ko)
|
2009-06-03 |
2022-09-16 |
이뮤노젠 아이엔씨 |
메이탄시노이드의 제조방법
|
US20120213705A1
(en)
|
2009-06-22 |
2012-08-23 |
Medimmune, Llc |
ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
|
WO2011066342A2
(en)
|
2009-11-24 |
2011-06-03 |
Amplimmune, Inc. |
Simultaneous inhibition of pd-l1/pd-l2
|
WO2011123903A1
(en)
*
|
2010-04-08 |
2011-10-13 |
Adelaide Research & Innovation Pty Ltd |
Chemokine receptor heteromultimers, compounds that bind thereto and uses thereof
|
UA116524C2
(uk)
|
2011-03-29 |
2018-04-10 |
Іммуноджен, Інк. |
Спосіб одержання кон'югата антитіло-майтансиноїд
|
MX2013011201A
(es)
|
2011-03-29 |
2013-12-16 |
Immunogen Inc |
Proceso para la elaboracion de conjugados de mejor homogeneidad.
|
CN109934744B
(zh)
|
2012-02-20 |
2023-09-05 |
株式会社诺瑞韩国 |
基于知识单元提供教育服务的方法、系统和计算机可读记录介质
|
WO2013179174A1
(en)
|
2012-05-29 |
2013-12-05 |
Koninklijke Philips N.V. |
Lighting arrangement
|
JP6321633B2
(ja)
|
2012-06-04 |
2018-05-09 |
ノバルティス アーゲー |
部位特異的標識法およびそれによって生成される分子
|
US20150344580A1
(en)
*
|
2012-06-05 |
2015-12-03 |
Eldar Kim |
Human Monoclonal Antibodies Against Human Chemokine Receptor CCR7
|
US20150307619A1
(en)
*
|
2012-12-13 |
2015-10-29 |
The Schepens Eye Research Institute, Inc. |
Use of C-C Chemokine Receptor Type 7 (CCR7) Inhibitors
|
WO2014124258A2
(en)
|
2013-02-08 |
2014-08-14 |
Irm Llc |
Specific sites for modifying antibodies to make immunoconjugates
|
PT2953976T
(pt)
|
2013-02-08 |
2021-06-23 |
Novartis Ag |
Sítios específicos de modificação de anticorpos para preparar imunoconjugados
|
CA2930614A1
(en)
|
2013-12-17 |
2015-06-25 |
Novartis Ag |
Cytotoxic peptides and conjugates thereof
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
MX2016011627A
(es)
|
2014-03-12 |
2016-11-29 |
Novartis Ag |
Sitios especificos para modificar anticuerpos con el fin de hacer inmunoconjugados.
|
MX2016016515A
(es)
|
2014-06-13 |
2017-04-27 |
Novartis Ag |
Derivados de auristatina y conjugados de los mismos.
|
US20190194315A1
(en)
|
2015-06-17 |
2019-06-27 |
Novartis Ag |
Antibody drug conjugates
|
DK3334457T3
(da)
*
|
2015-08-10 |
2020-09-21 |
Pepmab B V |
Humaniserede anti-CCR7-receptorantistoffer
|
JOP20190187A1
(ar)
*
|
2017-02-03 |
2019-08-01 |
Novartis Ag |
مترافقات عقار جسم مضاد لـ ccr7
|